|Summary sheet: 2C-I|
|Routes of Administration|
2,5-Dimethoxy-4-iodophenethylamine (also known as 2C-I) is a psychedelic substance of the phenethylamine class. It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.
2C-I was first synthesized and investigated for human activity by Alexander Shulgin in 1976 and later described in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved"). Its PiHKAL entry notes it for being "very colorful and active" but without "feelings of insight, revelation, or progress toward the true meaning of the universe." It first briefly gained some popularity in the late 1990s and early 2000s, where it was sold in several smart shops as a replacement for 2C-B following its scheduling in 1995. It also has a history of being sold online as a research chemical before becoming scheduled.
2C-I is typically used recreationally for its psychedelic as well as moderate stimulating and entactogenic effects. It has been explored as a potential stimulant nootropic in the 1-8mg dosage range.
Little data exists about the pharmacological properties, metabolism, and toxicity of 2C-I, and it has a limited history of human use. 2C-I is sometimes confused for the analog 25I-NBOMe (an abbreviated form of 2C-I-NBOMe). It is highly advised to use harm reduction practices if using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
2C-I, or 2,5-dimethoxy-4-iodophenethylamine, is a substituted phenethylamine comprising a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-I contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as an iodine atom attached to carbon R4 of the phenyl ring. 2C-I belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.
2C-I's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.
Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - In terms of its effects on the physical energy levels of the user, 2C-I is usually considered to be very energetic and stimulating in a fashion that is quite comparable to MDMA, although it is 'encouraged' instead of 'forced'.
- Spontaneous physical sensations - The "body high" of 2C-I is manifested as one of the most proportionally intense in comparison to almost all of the classical psychedelics. The sensation itself can be described as an intense and slightly uncomfortable energetic pins and needles sensation that constantly encompasses a person’s entire body. It is usually felt over every square inch of the skin but occasionally manifests itself in the form of a continuously shifting, tingling sensation that travels up and down the body in spontaneous waves. Alongside this, many users commonly report that the "body high" can be particularly uncomfortable and sometimes accompanied by dysphoric aches and urges to shift the position of one's body and prolonged tensing of unusual combinations of muscle groups.
- Physical euphoria - Feelings of frequent but unpredictable rushes of warm physical euphoria are extremely common. These can move from the top of the head downwards before enveloping one's whole body.
- Tactile enhancement
- Bodily control enhancement
- Stamina enhancement
- Increased heart rate
- Temperature regulation suppression
- Muscle contractions
- Muscle cramps
- Muscle spasms
- Appetite suppression
- Frequent urination
- Nausea - Mild to extreme nausea is consistently reported when consumed in moderate to high doses and either passes once the user has vomited or gradually fades by itself as the peak sets in.
- Pupil dilation
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as simplistic and bland in detail, slow and smooth but sometimes jittery in motion, static in appearance and unrealistic/cartoon-like in style.
- Colour shifting
- Environmental cubism - This effect is unique in that is it usually manifests simultaneously alongside or directly as a result of external geometry
- Environmental patterning
- Scenery slicing
- Symmetrical texture repetition
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of LSD or 2C-B than that of 2C-E, psilocin, or ayahuasca although it is much blander and less detailed. They can be comprehensively described as unstructured in their organization, algorithmic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colorful in scheme, glossy in color, both soft and sharp in their edges as well as equally rounded and angular in their corners. They seem high in algorithmic visuals such as fractals and at higher doses are significantly more likely to result in states of level 8A visual geometry over level 8B.
Like LSD, while 2C-I is capable of producing a full range of low and high level hallucinatory states, this is extremely rare and inconsistent at higher levels but common at lower ones.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - Although 2C-I is technically capable of producing hallucinatory states in a fashion that is on par with psilocin or DMT in its vividness and intensity, in comparison, these effects are extremely rare and inconsistent. Whilst traditional psychedelics such as LSA, ayahuasca and mescaline will induce internal hallucinations near consistently at level 5 geometry and above, 2C-I hallucinations will not extend beyond imagery and higher doses will for most simply go straight into level 8A visual geometry. This lack of consistently induced hallucinatory breakthroughs means that, for most, 2C-I is not as deep of an experience as certain other psychedelics.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
The head space of 2C-I is described by many as one which is relatively normal in its thought processes even at moderate to high doses. It is often said to lack insight when compared to that of 2C-E, psilocin and LSD.
- Empathy, affection, and sociability enhancement - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, affection and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
- Analysis enhancement
- Emotion enhancement or Emotion suppression
- Immersion enhancement
- Increased libido
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Time distortion
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
The toxicity and long-term health effects of recreational 2C-I use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-I is a research chemical with very little history of human usage.
Anecdotal reports from those who have tried 2C-I suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Tolerance and addiction potential
Although no formal studies have been conducted, it is not unreasonable to assume that as is the case with psychedelics in general, 2C-I is not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of 2C-I are built almost immediately after ingestion. After that, it takes about 3-5 days for the tolerance to be reduced to half and 7-10 days to be back at baseline (in the absence of further consumption). 2C-I presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-I all psychedelics will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
- Austria: 2C-I is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
- Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Canada: 2C-I is a schedule III controlled substance in Canada.
- Denmark: 2C-I is a controlled substance in Denmark.
- European Union: In December 2003, the European Council issued a binding order compelling all EU member states to ban 2C-I within three months.
- Germany: 2C-I is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of October 10, 1999. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Greece: 2C-I is a controlled substance in Greece.
- Ireland: 2C-I is a controlled substance in Ireland.
- Italy: 2C-I is a controlled substance in Italy.
- Latvia: 2C-I is a Schedule I controlled substance Latvia.
- The Netherlands: 2C-I is a controlled substance in the Netherlands.
- Poland: 2C-I is a controlled substance in Poland.
- Sweden: Sveriges riksdag added 2C-I to Schedule I ("substances, plant materials and fungi which normally do not have medical use") as a narcotic in Sweden as of March 16, 2004.
- Switzerland: Possession, production and sale is illegal.
- United Kingdom: 2C-I is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
- United States: As of July 9, 2012, 2C-I is a Schedule I substance in the U.S. under the Synthetic Drug Abuse Prevention Act of 2012, making possession, distribution and manufacture illegal.
- Alexander Shulgin - PiHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml
- Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p179 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
- Shulgin, A., & Shulgin, A. (1991). IsomerDesign: "PiHKAL" - #33 - 2C-I. Retrieved Jan 22, 2018.
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)
- Erowid.org, Legal Status of 2C-I
- "Dreizehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
- United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made